Speciality: Gastroenterology
Description:
A warm welcome to all the medical professionals in this interesting session of Tofacitinib in the treatment of Ulcerative Colitis.. We have Prof. Anand N. Malaviya, Dr Indrajit Agrawal, and Dr Sanjiv Kapoor to lead the session.
Ulcerative colitis treatment usually involves either medication therapy or surgery. Different categories of medications can help in treating ulcerative colitis.
Tofacitinib inhibits the process of intracellular signaling from the receptor to the cellular nucleus and inhibits the inflammation process via inhibition of the Janus kinases, which eventually helps in controlling different inflammatory diseases.
Oral formulation of tofacitinib has been approved for the treatment of patients with moderate–severe ulcerative colitis as Tofacitinib and other JAK inhibitors address an unmet need in the armamentarium of IBD therapy.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Patients face high out-of-pocket costs after incident cancer diagnosis
2.
In a study, immune detection of oral cancers is linked to obesity.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
5.
Common intracellular toxin could help fight leukemia
1.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
2.
The Latest Research on Chronic Granulomatous Disease and Promising New Treatments
3.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
4.
Florinef: Understanding Its Uses and Side Effects
5.
Uncovering the Subtle Signs of Leukemia: A Guide to Early Detection
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation